No insider purchase over the last 90 days. The latest, by Anders Lennart Bladh, Ribbskottet, was filed 04 May 2026.
Every trade that managers of XSpray Pharma AK disclose to Finansinspektionen is tracked on this page. Between 24 October 2025 and 24 October 2026, 3 insiders published 6 filings.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €40k) and 1 sale (1 insider, €0). The net balance comes to €40k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 board member. At €40k, the purchase published on 4 May 2026 by Anders Lennart Bladh, Ribbskottet is the largest of the period.
The last insider purchase was made public on 4 May 2026, 172 days ago. Filings reach the Finansinspektionen feed a median of 1 day after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.
Compared with its exchange (1,028 companies, median 9 filings), a count of 6 filings is below the norm. Looking back to 2017, when coverage begins, insiders filed 69 purchases and 23 sales.
In the same market, recent insider purchases at Dynavox Group AB and Rusta AB (publ) also feature in our signals. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
+3 other insiders
· cache
25 of 154 declarations
XSpray Pharma AK is a pharmaceutical company focused on developing innovative treatments. It is listed on the XSTO exchange.
Purchases our model currently ranks for the recommendations list.
All recommendations